U.S. Patent And Trademark Office Confirms Patentability Of The Formulation Claims Covering Merial’s FRONTLINE® Plus

Merial, a leading animal health pharmaceutical company, announced today the United States Patent and Trademark Office (USPTO) reconfirmed the patentability of formulation claims covering Merial’s FRONTLINE® Plus, the No. 1 flea and tick control product. “The ultimate result is that we expect some of the products infringing the formulation claims to be removed from the market,” said Dr. Judy Jarecki-Black, Esq., Merial’s head of Intellectual Property. “We are pleased that the Patent Office confirmed the patentability of Merial’s inventions directed at fipronil and (S)-methoprene containing spot-on compositions,” said Dr. Jarecki-Black. Merial is also pursuing litigation against other manufacturers in cases where it believes its patents have been violated. “We plan to continue to vigorously defend our patent rights and continue our strong support of the veterinary profession,” added Dr. Jarecki-Black.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards